186 related articles for article (PubMed ID: 28467780)
21. Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.
Mendonca J; Sharma A; Kachhap S
Asian J Androl; 2015; 17(3):435-6. PubMed ID: 25532579
[TBL] [Abstract][Full Text] [Related]
22. Retention of Interstitial Genes between
Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
[No Abstract] [Full Text] [Related]
23. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
Smit FP; Salagierski M; Jannink S; Schalken JA
BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
[TBL] [Abstract][Full Text] [Related]
24. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
25. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing.
Kannan K; Wang L; Wang J; Ittmann MM; Li W; Yen L
Proc Natl Acad Sci U S A; 2011 May; 108(22):9172-7. PubMed ID: 21571633
[TBL] [Abstract][Full Text] [Related]
26. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
[TBL] [Abstract][Full Text] [Related]
27. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.
Hermans KG; Bressers AA; van der Korput HA; Dits NF; Jenster G; Trapman J
Cancer Res; 2008 May; 68(9):3094-8. PubMed ID: 18451133
[TBL] [Abstract][Full Text] [Related]
28. The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing.
Cieslik M; Chugh R; Wu YM; Wu M; Brennan C; Lonigro R; Su F; Wang R; Siddiqui J; Mehra R; Cao X; Lucas D; Chinnaiyan AM; Robinson D
Genome Res; 2015 Sep; 25(9):1372-81. PubMed ID: 26253700
[TBL] [Abstract][Full Text] [Related]
29. Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer.
Chow A; Amemiya Y; Sugar L; Nam R; Seth A
Anticancer Res; 2012 Sep; 32(9):3629-41. PubMed ID: 22993300
[TBL] [Abstract][Full Text] [Related]
30. Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue.
Luo JH; Liu S; Zuo ZH; Chen R; Tseng GC; Yu YP
Am J Pathol; 2015 Jul; 185(7):1834-45. PubMed ID: 25963990
[TBL] [Abstract][Full Text] [Related]
31. Transcriptome sequencing to detect gene fusions in cancer.
Maher CA; Kumar-Sinha C; Cao X; Kalyana-Sundaram S; Han B; Jing X; Sam L; Barrette T; Palanisamy N; Chinnaiyan AM
Nature; 2009 Mar; 458(7234):97-101. PubMed ID: 19136943
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
[TBL] [Abstract][Full Text] [Related]
33. ChimPipe: accurate detection of fusion genes and transcription-induced chimeras from RNA-seq data.
Rodríguez-Martín B; Palumbo E; Marco-Sola S; Griebel T; Ribeca P; Alonso G; Rastrojo A; Aguado B; Guigó R; Djebali S
BMC Genomics; 2017 Jan; 18(1):7. PubMed ID: 28049418
[TBL] [Abstract][Full Text] [Related]
34. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
35. Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas.
Rathe SK; Popescu FE; Johnson JE; Watson AL; Marko TA; Moriarity BS; Ohlfest JR; Largaespada DA
Sci Rep; 2019 Jan; 9(1):358. PubMed ID: 30674975
[TBL] [Abstract][Full Text] [Related]
36. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
37. Signaling networks in TMPRSS2-ERG positive prostate cancers: Do we need a Pied Piper or sharpshooter to deal with "at large" fused oncoprotein.
Lin X; Qureshi MZ; Romero MA; Yaylim I; Arif S; Ucak I; Fayyaz S; Farooqi AA; Mansoor Q; Ismail M
Cell Mol Biol (Noisy-le-grand); 2017 Feb; 63(2):1-8. PubMed ID: 28364793
[TBL] [Abstract][Full Text] [Related]
38. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
39. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
Kiflemariam S; Mignardi M; Ali MA; Bergh A; Nilsson M; Sjöblom T
J Pathol; 2014 Oct; 234(2):253-61. PubMed ID: 24931216
[TBL] [Abstract][Full Text] [Related]
40. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
Mitani Y; Liu B; Rao PH; Borra VJ; Zafereo M; Weber RS; Kies M; Lozano G; Futreal PA; Caulin C; El-Naggar AK
Clin Cancer Res; 2016 Feb; 22(3):725-33. PubMed ID: 26631609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
